KEY MILESTONES & STRATEGIC INSIGHTS
- €750,000 Grant: Funding for an industrial-scale pilot plant, advancing both defense and civilian applications
- Legitimate Technological Breakthrough: HPQ achieves “a true technological breakthrough” according to patent examiner recognizing process as “unprecedented, with no prior art”
- Third-Party Validation: The technology has passed rigorous testing, earning recognition from patent examiners and drawing attention from both military and industrial sectors in Europe
“By providing the armed forces with the means to produce hydrogen on the ground, this innovation could represent a major step forward in achieving energy autonomy for European & North American armed forces. It strengthens their ability to operate independently without relying on conventional energy networks”
In a major leap forward, HPQ’s affiliate, Novacium, has been pre-selected by the French Defense Procurement Agency (DGA) for a prestigious €750,000 grant under the RAPID program, designed to support dual-use technologies with both military and civilian applications. This funding, which covers 75% of the costs, will be directed toward building an industrial-scale pilot plant for METAGENE™, an autonomous, on-demand hydrogen production system that uses a bulk, non-explosive aluminum-silicon-based alloy as the energy source.
“This grant is a game-changer—proof that our on-demand hydrogen production system is ready to meet the rigorous standards of military and civilian applications alike,” said Bernard Tourillon, President and CEO of HPQ Silicon Inc. and NOVACIUM SAS.
UNIQUE TECHNOLOGY DRIVING MARKET DISRUPTION
METAGENE™ represents a transformative shift in hydrogen production. Unlike traditional methods that require electricity, high pressure, and complex logistics, this system operates autonomously using a safe and low-cost alloy to produce hydrogen on-demand. Its simplicity, safety, and scalability make it ideal for remote, off-grid applications, especially in military operations. The technology is positioned to disrupt both the hydrogen energy sector and military energy solutions, with potential for global adoption.
STRONG THIRD-PARTY VALIDATION AND MARKET POTENTIAL
The patent for METAGENE™ has progressed to Patent Pending status, with a highly positive research report from the patent examiner noting that no prior art could be found. This recognition underscores the uniqueness and robustness of the technology, setting it apart in the crowded hydrogen market. With a 12-month operational timeline, the pilot plant is expected to demonstrate real-world hydrogen production capabilities, attracting further investment and commercial interest.
“It is rare, in a field as established as hydrolysis, to achieve a true technological breakthrough,” said Dr. Jed Kraiem, Chief Operating Officer of Novacium. “The recognition of our process as unprecedented, with no prior art, demonstrates that it is still possible to push the boundaries of innovation, even in mature fields.”
LOOKING AHEAD: TREMENDOUS MARKET POTENTIAL
The global hydrogen market is set for significant growth, and METAGENE™ is well-positioned to capitalize on this expansion, particularly with HPQ’s exclusive North American rights. The technology’s low carbon footprint, autonomous operation, and military applications ensure it stands out as a game-changing solution for both defense and industrial sectors worldwide.
As interest builds, this breakthrough technology has the potential to attract global attention and investment, solidifying HPQ’s position as a leader in the rapidly growing hydrogen space.
This is just the beginning.
Tags: #Smallcap